外照射放疗不同分割方案对食管癌姑息治疗的效果
该回顾性研究纳入2009至2015年间接受姑息性外照射放疗的205例不可治愈食管癌患者,比较20 Gy/5次、30 Gy/10次和39 Gy/13次三种方案的症狀控制与生存。结果显示72%患者症状改善且各方案无差异,中位总生存分别为4.6、5.2和9.7个月,较高剂量与更长的二次干预时间相关。
要点
- 三种姑息外照射方案症状改善率均为72%,方案间无差异。
- 20 Gy、30 Gy、39 Gy组中位总生存分别为4.6、5.2、9.7个月。
- 30 Gy和39 Gy较20 Gy显著延长至二次干预时间。
核心结论
- 姑息性外照射放疗对症状性食管癌提供良好症状控制,较高剂量方案与更长的二次干预时间相关,应基于预期生存选择方案。
研究设计与样本
- 回顾性研究,纳入2009年1月至2015年12月接受姑息性外照射放疗的食管癌患者205例,比较20 Gy/5次、30 Gy/10次和39 Gy/13次三种方案。
主要发现
- 72%患者症状改善,各方案间无差异。
- 20 Gy、30 Gy和39 Gy组中位总生存分别为4.6个月(95%CI 2.6-6.6)、5.2个月(95%CI 3.7-6.7)和9.7个月(95%CI 6.9-12.5)。
- 体力状况差(HR 2.25,95%CI 1.53-3.29)、复发食管癌(HR 1.69,95%CI 1.15-2.47)和远处转移(HR 1.73,95%CI 1.27-2.35)与更差总生存显著相关。
- 30 Gy和39 Gy较20 Gy与更长至二次干预时间相关(校正病因特异HR分别为0.50(95%CI 0.25-0.99)和0.27(95%CI 0.13-0.56))。
关键数值与推荐
- 症状改善率72%,各方案间无差异。
- 中位总生存:20 Gy组4.6个月(95%CI 2.6-6.6),30 Gy组5.2个月(95%CI 3.7-6.7),39 Gy组9.7个月(95%CI 6.9-12.5)。
- 至二次干预的校正病因特异HR:30 Gy vs 20 Gy为0.50(95%CI 0.25-0.99),39 Gy vs 20 Gy为0.27(95%CI 0.13-0.56)。
临床怎么用
- 对预期生存较短的患者,选择较短疗程以避免不必要的长疗程治疗。
- 对预期生存较长的患者,选择较高剂量方案以降低二次干预风险。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Although external beam radiotherapy (EBRT) is frequently used for palliative treatment of patients with incurable esophageal cancer, the optimal schedule for symptom control is unknown. This retrospective study evaluated three EBRT schedules for symptom control and investigated possible prognostic factors associated with second intervention and overall survival (OS). MATERIAL AND METHODS: Patients with esophageal cancer treated with EBRT with palliative intent between January 2009 and December 2015 were evaluated. Univariate and multivariate Cox regression models estimated the effect of treatment schedule (20 Gy in 5 fractions, 30 Gy in 10 fractions or 39 Gy in 13 fractions) on OS. To study the effect of prognostic factors on time to second intervention (repeat EBRT, intraluminal brachytherapy or stent placement) a competing risk model with death as competing event was used. RESULTS: 205 patients received 20 Gy (31%), 30 Gy (38%) or 39 Gy (32%). Improvement of symptoms was observed in 72% with no differences between schedules. Median OS after 20 Gy, 30 Gy and 39 Gy was 4.6 months (95%CI 2.6-6.6), 5.2 months (95%CI 3.7-6.7) and 9.7 months (95%CI 6.9-12.5), respectively. Poor performance status (HR 2.25 (95%CI 1.53-3.29)), recurrent esophageal cancer (HR 1.69 (95%CI 1.15-2.47)) and distant metastasis (HR 1.73 (95%CI 1.27-2.35)) were significantly related to worse OS. Treatment with 30 Gy and 39 Gy was related to longer time to second intervention compared to 20 Gy (adjusted cause specific HR 0.50 (95%CI 0.25-0.99) and 0.27 (95%CI 0.13-0.56), respectively). CONCLUSIONS: Palliative EBRT provides good symptom control in patients with symptomatic esophageal cancer. A higher dose schedule was related to a longer time to second intervention. Hence, selection based on life expectancy is vital to prevent unnecessary long treatment schedules in patients with expected short survival, and limit the chance of second intervention when life expectancy is longer.
引用
- Walterbos NR, Fiocco M, Neelis KJ, et al. Effectiveness of several external beam radiotherapy schedules for palliation of esophageal cancer. Clin Transl Radiat Oncol. 2019. PMID: 31193091. doi:10.1016/j.ctro.2019.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。